Nanobiotix shares rise 3% and rank among the top performers of the SBF 120

A stock that moves back above its short-term moving averages despite a weekly decline

Nanobiotix gains 2.98% to €27.68, while the SBF 120 rises 0.52%: the stock ranks among the strongest gainers in the index. The stock nonetheless remains down 8.83% over seven days, but it retains a gain of 21.08% over one month, which illustrates the magnitude of recent back-and-forth movements.

The price is now above the MM20 (€24.44, a gap of 13.26%) and barely above the MM50 (€27.50, a gap of 0.65%), a zone it had been contesting in recent days.

The MM200 (€29.44) remains, by contrast, 5.98% above the price, while the RSI at 55 signals neither overbought nor oversold conditions. Nanobiotix is listed in Paris and on the Nasdaq as ADSs, the same company on two exchanges, with the Nasdaq having closed up 1.44% yesterday.

A cash position of €110.9 million announced in September to fund operations through 2029

When it published its first-half 2026 results on September 24, the company stated that its cash position of €110.9 million would allow it to finance its operations through 2029. It also specified that it had no substantial doubt about its ability to continue as a going concern.

The clinical pipeline remains centered on NBTXR3 (JNJ-1900), a radioenhancer combined with radiotherapy and developed with Johnson & Johnson: on October 24, at the ESMO congress in Madrid, the melanoma cohort of the phase 1 study showed a median overall survival of 17.8 months in patients resistant to anti-PD-1 therapies.

In terms of price levels, support stands at €18.85 and resistance at €30.36, representing a gap of 9.7% from the current price.